Bagsværd, Denmark, 12 October 2026 – Novo Nordisk A/S has initiated a share repurchase program that aims to buy back up to DKK 15 billion worth of shares over the next year. This strategic move, which is set to enhance shareholder value, indicates the company's confidence in its financial position and future growth prospects.

According to the filing, the repurchase program began on 6 May 2026 and will run until 1 February 2027. Under this program, Novo Nordisk plans to repurchase B shares for an amount up to DKK 11,200,000,010.45. The company has already made significant progress, having repurchased a total of 37,849,179 B shares at an average price of DKK 278.97 per share, amounting to a transaction value of DKK 10,558,876,422 since the program's inception.

Background

Novo Nordisk A/S is a global healthcare company specializing in the development of pharmaceutical preparations, particularly in diabetes care and hormone replacement therapy. The company is listed on the New York Stock Exchange under the ticker symbol NVO and on Nasdaq Copenhagen as Novo-B. It is recognized as a large accelerated filer and has a fiscal year ending on December 31.

What the Filing Says

The filing states, "Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026." It also details transactions made under the share repurchase program, highlighting the number of shares repurchased and their average purchase prices.

Impact

This share repurchase program is likely to affect shareholders positively by potentially increasing the value of remaining shares. It reflects a broader trend in the pharmaceutical industry, where companies are increasingly focusing on returning capital to investors. Competitors may observe this move and consider similar strategies to enhance shareholder returns.

What's Next

Further details regarding transactions made under the share repurchase program will be published on Novo Nordisk's website. The company is expected to continue executing this program until the specified end date, with updates on the progress likely to be communicated through future filings.